Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Nephrology | Urology
Search Medical Condition
Bladder Disorders Clinical Trials
A listing of Bladder Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (91) clinical trials
The REGENERATE Study (Research Study for Treatment of NASH (Non-Alcoholic Steato-Hepatitis)/Advanced Fatty-Liver Disease)
The purpose of this study is to find out how safe and effective OCA may be in delaying or preventing specific medical conditions or health related issues that can occur in patients with NASH and evidence of liver fibrosis. The investigational drug, OCA, is a modified (man-made) version of a ...
A Pilot, Prospective, Randomized, Controlled, Multicenter Technical Feasibility Clinical Study Comparing Standard Anastomosis Closure Technique to Standard Closure Techniques Plus Sylys® Surgical Sealant
The Cohera Sylys® Surgical Sealant study is a prospective, randomized, controlled, multicenter technical feasibility clinical study comparing standard anastomosis closure technique (Control) to standard closure techniques plus Sylys® Surgical Sealant (Test) during colorectal and ileorectal anastomosis procedures.
Fatty Liver Research – Compensation up to $1,440
Clinical Trials of Texas, Inc. is enrolling now for an investigational medication for patients with non-alcoholic fatty liver disease. Study participation is approximately 98 days. Qualified participants will receive study-related medical care from a board-certified physician, study medications, exams and evaluations. Qualified participants will help further medical science for treatment ...
A randomized,double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib. The study is composed of 3 periods: A ...
Have you or someone you know been diagnosed with Irritable Bowel Syndrome? If so, there is now an opportunity to join a new research study.
Qualified Participants: Will receive study medication or placebo, study-related testing, physical exams, and lab work at no charge.
Have you been diagnosed with Eosinophilic Esophagitis? (EOE) Enrolling in this study is one of the best ways to actively participate in the search for a cure for Eosinophilic Esophagitis! Learn more, contact us today!
Fluticasone in Eosinophilic esophagitis (FLUTE)
Do you have a fatty liver? (Nonalcoholic Steatohepatitis) You can be the one today to help us find a better way to treat patients who are currently suffering from a fatty liver disease.
Do you have liver cirrhosis as a result of Nonalcoholic Steatohepatitis (NASH)? Participating in research is one of the best ways to actively participate in the search for a cure! Call today to learn more!
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
The primary objective of this study is to evaluate whether SEL can cause fibrosis regression and reduce progression to cirrhosis and associated complications in subjects with NASH and bridging (F3) fibrosis. The secondary objective of this study is to assess the safety and tolerability of SEL in subjects with NASH ...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)
To evaluate whether selonsertib (SEL, previously known as GS-4997) can cause fibrosis regression and reduce associated complications in subjects with cirrhosis due to NASH.
Nonalcoholic Fatty Liver / Nonalcoholic steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH) is an advanced form of fatty liver disease. It is caused by excess fat in the liver that leads to inflammation and tissue injury. People with type 2 diabetes, obesity, high cholesterol, insulin resistance, and high blood pressure may have NASH. ACRC Trials is conducting a research ...
